Skip to main content
. 2022 Mar 9;11(6):e024521. doi: 10.1161/JAHA.121.024521

Table 1.

Patient Characteristics Across Quartiles of Mean LA Voltage

Variables

Q1 (<4.2 mV)

n=35

Q2 (4.2–5.6 mV)

n=35

Q3 (5.7–7.0 mV)

n=35

Q4 (≥7.1 mV)

n=35

Control

n=13

P for trend in Q1–Q4 P value, Q4 vs control
Age, y 73±8 71±6 68±8 62±13 55±10 <0.001* 0.059
Females, n (%) 18 (51) 11 (31) 9 (26) 4 (11) 5 (38) 0.001* 0.047*
Non‐PAF, n (%) 29 (83) 22 (63) 18 (51) 14 (40) <0.001*
BMI, kg/m2 24.1±3.4 25.3±3.3 24.0±4.1 25.3±3.9 23.9±5.1 0.749 0.358
History of cerebral infarction 4 (11) 1 (3) 4 (11) 3 (9) 0 (0) 1.000 0.552
History of congestive heart failure, n (%) 9 (26) 5 (14) 5 (14) 2 (6) 0 (0) 0.026* 1.000
Hypertension, n (%) 20 (57) 20 (57) 14 (40) 16 (46) 1 (8) 0.173 0.018*
Diabetes, n (%) 6 (17) 4 (11) 4 (11) 9 (26) 1 (8) 0.358 0.247
CHA2DS2‐VASc score (IQR) 3 (2–4) 2 (2–3) 2 (1–3) 2 (1–3) 0 (0–1) <0.001* 0.009*
eGFR, mL/min per 1.73 m2 51±21 58±18 61±17 65±18 69±9 0.001* 0.242
LVEF, % 61±12 65±11 63±14 70±11 68±7 <0.001* 0.380
LA diameter, mm 42±5 43±6 39±5 38±6 34±6 <0.001* 0.094
LA volume, mL 174±47 169±44 140±38 141±45 <0.001*
LA volume/BSA, mL/m2 108±26 99±23 84±19 78±22 <0.001*
Global LA voltage (VGLA), mV 3.0±0.8 4.9±0.4 6.3±0.4 8.5±1.3 8.5±1.0 <0.001* 0.946
Atrial biopsy, n 4 7 7 10
%fibrosis, % 13.9±2.8 9.2±4.1 7.1±3.8 5.1±2.9 <0.001*
Voltage at biopsy site, mV 5.8±0.4 8.4±1.4 9.2±1.8 11.8±2.7 <0.001*

*Significant value (P < 0.05).

AT indicates atrial tachycardia; BMI, body mass index; BSA, body surface area; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LA, left atrium; LVEF, left ventricular ejection fraction; PAF, paroxysmal atrial fibrillation; Q1–4, first to fourth quartile; and RA, right atrium.